Arch Therapeutics to Present at Source Capital Group's 2017 Disruptive Growth & Healthcare Conference

Accesswire 13-Jan-2017 1:01 PM

WESTPORT, CT / ACCESSWIRE / January 13, 2017 / Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device (AC5) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, will present at the Source Capital Group's 2017 Disruptive Growth & Healthcare Conference.

Chief Executive Officer Terrence W. Norchi, MD will provide a corporate update, discuss near-term milestones, and meet with investors. The conference will be held at the Convene Conference Center, 730 3rd Avenue in New York City.

If you are an investor and wish to register to attend the Company's presentation or schedule a meeting at the conference, you may find information by clicking on the following link: www.disruptnyc.com.

About Arch Therapeutics, Inc.

Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as AC5, is being designed to achieve hemostasis in minimally invasive and open surgical procedures. Find out more at www.archtherapeutics.com.

About Source Capital Group, Inc.

The Investment Banking Group at Source Capital offers a wealth of Wall Street experience to the under-served small cap company sector through its seasoned professionals. They have successfully funded both public and private companies, with an emphasis on Structured Credit and unique equity capital markets transactions, creating tailor-made solutions to enhance their clients' balance sheets. Source Capital Group began as an independent firm specializing in small to medium-sized investment banking transactions. Since 1992, it has grown into a full-service financial institution, while adhering to the highest standards of quality and integrity.

SOURCE: Arch Therapeutics, Inc.